Gilead Sciences Receives Subpoena from U.S. Department of Health & Human Services Regarding Ranexa®
August 14 2009 - 6:00PM
Business Wire
Gilead Sciences, Inc. (Nasdaq:GILD) announced today that it has
received a subpoena from the Office of the Inspector General of the
Department of Health and Human Services requesting documents
regarding the development, marketing and sales of Ranexa®
(ranolazine). Ranexa is approved for the treatment of chronic
angina and was developed and originally commercialized by CV
Therapeutics, a company that Gilead acquired in April 2009.
About Gilead
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of
unmet medical need. The company’s mission is to advance the care of
patients suffering from life-threatening diseases worldwide.
Headquartered in Foster City, California, Gilead has operations in
North America, Europe and Australia.
For more information on Gilead
Sciences, please visit www.gilead.com or call the Gilead Public
Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jul 2023 to Jul 2024